Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus Corporation (Nasdaq: CERS) reported strong fourth quarter 2022 revenue of $51.3 million, a 2% increase year-over-year, with product revenue rising 10% to $44.0 million. Full-year 2022 product revenue reached $162.0 million, up 24% from 2021. Despite a dip in government contract revenue by 29% in Q4, the company reiterated its 2023 product revenue guidance of $165-170 million. Product gross profit hit a record high of $24.5 million, reflecting a margin of 55.7%. Operational expenses rose by 11% in Q4 to $41.8 million, while the net loss for Q4 was $13.6 million. As of December 31, 2022, Cerus had $102.2 million in cash and equivalents.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 PM ET that same day, where management will discuss the results and provide a business outlook. The live webcast can be accessed via the Investor Relations page on the Cerus website. A replay will be available approximately three hours post-call until March 14, 2023. Cerus is focused on ensuring the safety of the global blood supply, offering advanced technologies like the INTERCEPT Blood System.
Cerus Corporation (CERS) announced its participation in two upcoming investor conferences. CEO William ‘Obi’ Greenman will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14-15. He, along with CFO Kevin Green, will partake in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8 at 1:30 PM EST, with a live webcast available at this link. Cerus, based in Concord, California, is focused on securing the global blood supply, offering the only pathogen-reduction system for platelets and plasma with CE mark and FDA approval.
Cerus Corporation reported preliminary product revenues for Q4 2022 of
Cerus Corporation (NASDAQ: CERS) announced that its COO, Vivek Jayaraman, will participate in two upcoming conferences. He is scheduled to present at the Stifel 2022 Healthcare Conference on November 16 at 1:50 p.m. EST in New York and at the Stephens Annual Investment Conference on November 17 at 12:00 p.m. EST in Nashville, TN. To access the webcasts, visit ir.cerus.com. Cerus is focused on ensuring the safety of the global blood supply with its INTERCEPT Blood System, already approved in various regions.
Cerus Corporation (CERS) reported third quarter 2022 total revenue of $46.3 million, a 10% year-over-year increase, driven by $39.6 million in product revenue. Despite a 6% foreign exchange headwind, product gross profit rose to $21.9 million, with a gross margin of 55.4%. The net loss narrowed to $8.5 million or $0.05 per share. Cerus has secured a $9.1 million contract with the DoD for trauma treatment development and expects full-year product revenue guidance between $160 million and $162 million.
Cerus Corporation has been awarded a
Cerus Corporation (Nasdaq:CERS) has received approval from Health Canada to extend the storage life of platelets treated with the INTERCEPT Blood System from five days to seven days. This approval supports Cerus' partnership with Canadian Blood Services and aims to enhance the availability of pathogen-reduced platelets across Canada. The extension will allow better utilization of platelet supply, minimizing waste and safeguarding against pathogens. Canadian Blood Services manufactures approximately 115,000 platelet doses annually.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call and webcast will be held at 4:30 P.M. ET that day, where management will discuss financials and business outlook. The event can be accessed via the Cerus Investor Relations page. A replay will be available approximately three hours post-call until November 17, 2022. The company focuses on safeguarding the blood supply with its INTERCEPT Blood System, which is FDA approved for platelets and plasma.
Cerus Corporation (Nasdaq:CERS) reported its participation in the 2022 AABB Annual Meeting in Orlando, FL from October 1-4. This marks the conference's first in-person event since 2019. Cerus will present several abstracts highlighting the benefits of the INTERCEPT Blood System for Platelets and Cryoprecipitation. Key presentations include a plenary session on platelet safety and storage and a dedicated industry workshop. The INTERCEPT systems are pivotal for pathogen reduction in blood products and have received both CE mark and FDA approval.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
